Results 21 to 30 of about 6,483 (202)
Pharmacology Research & PerspectivesUlotaront (SEP‐363856) is a TAAR1 agonist, with 5‐HT1A agonist activity, currently in clinical development for the treatment of schizophrenia. In vitro studies indicate ulotaront is an OCT2‐specific inhibitor with IC50 of 1.27 μM.
Guangqing Xiao +5 more
doaj +2 more sources
Archives of Pharmaceutical Sciences Ain Shams University, 2022 Renal Organic Cation Transporter 2 (OCT2) plays a major role in metformin elimination. Daclatasvir, a Direct-Acting Antiviral (DAA), is an OCT2 inhibitor.
Mohamed Raslan +2 more
doaj +1 more source
OCT2 and MATE1 Provide Bidirectional Agmatine Transport [PDF]
Molecular Pharmaceutics, 2010 Agmatine is a biogenic amine (l-arginine metabolite) of potential relevance to several central nervous system (CNS) conditions. The identities of transporters underlying agmatine and polyamine disposition in mammalian systems are not well-defined.
Tate N, Winter +2 more
openaire +2 more sources
Acta Pharmaceutica Sinica B, 2023 Body is equipped with organic cation transporters (OCTs). These OCTs mediate drug transport and are also involved in some disease process. We aimed to investigate whether liver failure alters intestinal, hepatic and renal Oct expressions using bile duct ...
Shijin Hong +7 more
doaj +1 more source
Multiple Oct2 isoforms are generated by alternative splicing [PDF]
Nucleic Acids Research, 1991 The interaction of the Oct2 transcription factor with the cognate octamer motif ATGCAAAT is a critical determinant of the lymphoid-specific expression of immunoglobulin genes. Ectopic expression of cloned Oct2 cDNA was shown to be sufficient to reconstitute at least some aspects of this regulation in non-lymphoid cells.
T. Wirth +4 more
openaire +3 more sources
Cell Death and Disease, 2023 MYC controls most of the non-coding genome. Several long noncoding transcripts were originally identified in the human B cell line P496-3 and then shown to be required for MYC-driven proliferation of Burkitt lymphoma-derived RAMOS cells.
Daniel García-Caballero +2 more
doaj +1 more source
Translational Psychiatry, 2023 Selective serotonin reuptake inhibitors (SSRI) are common first-line treatments for major depression. However, a significant number of depressed patients do not respond adequately to these pharmacological treatments.
Alejandro Orrico-Sanchez +10 more
doaj +1 more source
Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-induced Peripheral Neurotoxicity
Cancer Research Communications, 2022 Oxaliplatin-induced peripheral neurotoxicity (OIPN) is a debilitating side effect that afflicts approximately 90% of patients that is initiated by OCT2-dependent uptake of oxaliplatin in dorsal root ganglion (DRG) neurons. The antidepressant drug duloxetine has been used to treat OIPN, although its usefulness in preventing this side effect remains ...
Mahesh R. Nepal +10 more
openaire +2 more sources
Cloning and Functional Characterization of Dog OCT1 and OCT2: Another Step in Exploring Species Differences in Organic Cation Transporters [PDF]
, 2022 OCT1 and OCT2 are polyspecific membrane transporters that are involved in hepatic and renal drug clearance in humans and mice. In this study, we cloned dog OCT1 and OCT2 and compared their function to the human and mouse orthologs.
Meyer, Marleen Julia +16 more
core +1 more source
Repositioning of Lansoprazole as a Protective Agent Against Cisplatin-Induced Ototoxicity
Frontiers in Pharmacology, 2022 Cisplatin (CDDP) is a well-known chemotherapeutic drug approved for various cancers. However, CDDP accumulates in the inner ear cochlea via organic cation transporter 2 (OCT2) and causes ototoxicity, which is a major clinical limitation.
Eri Wakai +6 more
doaj +1 more source